BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38590858)

  • 1. Integrated analysis of scRNA-seq and bulk RNA-seq identifies
    Lai W; Xie R; Chen C; Lou W; Yang H; Deng L; Lu Q; Tang X
    Heliyon; 2024 Apr; 10(7):e28490. PubMed ID: 38590858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A chemotherapy response prediction model derived from tumor-promoting B and Tregs and proinflammatory macrophages in HGSOC.
    Xi Y; Zhang Y; Zheng K; Zou J; Gui L; Zou X; Chen L; Hao J; Zhang Y
    Front Oncol; 2023; 13():1171582. PubMed ID: 37519793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of monocyte-related prognosis model based on comprehensive analysis of bulk RNA-seq and single-cell RNA-seq in high-grade serous ovarian cancer.
    Xu Y; Tan S; Huang W; Wang YX
    Medicine (Baltimore); 2023 Dec; 102(50):e36548. PubMed ID: 38115318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
    Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
    BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study of the clinical significance of ETAR mRNA expression in high-grade serous ovarian cancer and the inhibitory effect of ETAR derived fusion polypeptide on cancer progression].
    Zhang YL; Xia XK; Zhang M
    Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):930-938. PubMed ID: 38123199
    [No Abstract]   [Full Text] [Related]  

  • 6. Single-cell and spatial transcriptome sequencing uncover a platinum-resistant cluster overexpressed TACSTD2 in high-grade serous ovarian cancer.
    Han X; Gao Y; Jiang M; Li Z; Guo J; Li Y; Yi J; Hou L; Cheng J; Feng L; Jin Y; Zhao X; Yue W
    J Cancer; 2024; 15(11):3427-3440. PubMed ID: 38817863
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of estrogen response-associated STRA6+ granulosa cells within high-grade serous ovarian carcinoma by single-cell sequencing.
    Liu X; Chen Z; Zhang L
    Heliyon; 2024 Mar; 10(6):e27790. PubMed ID: 38509903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
    Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
    Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
    Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
    Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the cellular and molecular differences between ovarian clear cell carcinoma and high-grade serous carcinoma using single-cell RNA sequencing and GEO gene expression signatures.
    Guo D; Zhang S; Gao Y; Shi J; Wang X; Zhang Z; Zhang Y; Wang Y; Zhao K; Li M; Wang A; Wang P; Gou Y; Zhang M; Liu M; Zhang Y; Chen R; Sun J; Wang S; Wu X; Liang Z; Chen J; Lang J
    Cell Biosci; 2023 Jul; 13(1):139. PubMed ID: 37525249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
    El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
    Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer.
    Weigert M; Cui XL; West-Szymanski D; Yu X; Bilecz AJ; Zhang Z; Dhir R; Kehoe M; Zhang W; He C; Lengyel E
    Gynecol Oncol; 2024 Mar; 182():82-90. PubMed ID: 38262243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FBXO2 Promotes Proliferation of Endometrial Cancer by Ubiquitin-Mediated Degradation of FBN1 in the Regulation of the Cell Cycle and the Autophagy Pathway.
    Che X; Jian F; Wang Y; Zhang J; Shen J; Cheng Q; Wang X; Jia N; Feng W
    Front Cell Dev Biol; 2020; 8():843. PubMed ID: 32984335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAF4 promotes the malignant progression of high-grade serous ovarian cancer by activating YAP pathway.
    Luo X; Cao J; Zhang C; Huang H; Liu J
    Biochem Biophys Res Commun; 2022 Oct; 627():68-75. PubMed ID: 36029535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAF-Associated Paracrine Signaling Worsens Outcome and Potentially Contributes to Chemoresistance in Epithelial Ovarian Cancer.
    Wessolly M; Mairinger E; Borchert S; Bankfalvi A; Mach P; Schmid KW; Kimmig R; Buderath P; Mairinger FD
    Front Oncol; 2022; 12():798680. PubMed ID: 35311102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer.
    Hoffmann I; Dragomir MP; Monjé N; Keunecke C; Kunze CA; Schallenberg S; Marchenko S; Schmitt WD; Kulbe H; Sehouli J; Braicu IE; Jank P; Denkert C; Darb-Esfahani S; Horst D; Sinn BV; Sers C; Bischoff P; Taube ET
    Neoplasia; 2023 Oct; 44():100934. PubMed ID: 37703626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.
    Buttarelli M; Ciucci A; Palluzzi F; Raspaglio G; Marchetti C; Perrone E; Minucci A; Giacò L; Fagotti A; Scambia G; Gallo D
    J Exp Clin Cancer Res; 2022 Feb; 41(1):50. PubMed ID: 35120576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer.
    Todeschini P; Salviato E; Romani C; Raimondi V; Ciccarese F; Ferrari F; Tognon G; Marchini S; D'Incalci M; Zanotti L; Ravaggi A; Odicino F; Sartori E; D'Agostino DM; Samaja M; Romualdi C; Bignotti E
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.